{"id":416171,"date":"2021-01-18T19:34:24","date_gmt":"2021-01-19T00:34:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=416171"},"modified":"2021-01-18T19:34:24","modified_gmt":"2021-01-19T00:34:24","slug":"gensight-biologics-announces-its-2021-financial-calendar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/","title":{"rendered":"GenSight Biologics Announces its 2021 Financial Calendar"},"content":{"rendered":"

<\/p>\n

GenSight Biologics Announces its 2021 Financial Calendar<\/b><\/p>\n

PARIS–(BUSINESS WIRE<\/a>)–
\nRegulatory News:\n<\/p>\n

\nGenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021.\n<\/p>\n\n\n\n\n\n\n\n\n\n
\n

Information<\/b><\/p>\n<\/td>\n

\n

Date* <\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n2020 4Q Cash Position\n<\/p>\n<\/td>\n

\n

\nJanuary 19, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2020 Full-Year Financial Update and Statements\n<\/p>\n<\/td>\n

\n

\nMarch 10, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2021 1Q Cash Position\n<\/p>\n<\/td>\n

\n

\nApril 20, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAnnual General Meeting\n<\/p>\n<\/td>\n

\n

\nApril 29, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2021 First-Half Financial Update and Statements\n<\/p>\n<\/td>\n

\n

\nJuly 29, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2021 3Q Cash Position\n<\/p>\n<\/td>\n

\n

\nOctober 19, 2021\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2021 4Q Cash Position\n<\/p>\n<\/td>\n

\n

\nJanuary 18, 2022\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

* This financial calendar is provided for information only and may be subject to changes. The Company\u2019s updated financial calendar is available on its corporate website.<\/i><\/p>\n

About GenSight Biologics <\/b><\/p>\n

\nGenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics\u2019 pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics\u2019 product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics\u2019 lead product candidate, LUMEVOQ\u00ae<\/sup> (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210118005442\/en\/<\/a><\/span><\/p>\n

GenSight Biologics
\n<\/b>
Chief Financial Officer
\n
Thomas Gidoin
\n
tgidoin@gensight-biologics.com
\n<\/a>
+33 (0)1 76 21 72 20\n<\/p>\n

RooneyPartners
\n<\/b>
Media Relations
\n
Marion Janic
\n
mjanic@rooneyco.com
\n<\/a>
+1-646-537-5649\n<\/p>\n

LifeSci Advisors
\n<\/b>
Investor Relations
\n
Guillaume van Renterghem
\n
gvanrenterghem@lifesciadvisors.com
\n<\/a>
+41 (0)76 735 01 31\n<\/p>\n

Orpheon Finance
\n<\/b>
Retail Investors
\n
James Palmer
\n
j.palmer@orpheonfinance.com
\n<\/a>
+33 (0)7 60 92 77 74\n<\/p>\n

KEYWORDS:<\/b> Europe United States North America France<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Genetics Other Health General Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

GenSight Biologics Announces its 2021 Financial Calendar PARIS–(BUSINESS WIRE)– Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021. Information Date* 2020 4Q Cash Position January 19, 2021 2020 Full-Year Financial Update and Statements March 10, 2021 2021 1Q Cash Position April 20, 2021 Annual General Meeting April 29, 2021 2021 First-Half Financial Update and Statements July 29, 2021 2021 3Q Cash Position October 19, 2021 2021 4Q Cash Position January 18, 2022 * This financial calendar is provided for information only and may be subject to changes. The Company\u2019s updated financial … <\/p>\n

Continue reading “GenSight Biologics Announces its 2021 Financial Calendar”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-416171","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GenSight Biologics Announces its 2021 Financial Calendar PARIS–(BUSINESS WIRE)– Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021. Information Date* 2020 4Q Cash Position January 19, 2021 2020 Full-Year Financial Update and Statements March 10, 2021 2021 1Q Cash Position April 20, 2021 Annual General Meeting April 29, 2021 2021 First-Half Financial Update and Statements July 29, 2021 2021 3Q Cash Position October 19, 2021 2021 4Q Cash Position January 18, 2022 * This financial calendar is provided for information only and may be subject to changes. The Company\u2019s updated financial … Continue reading "GenSight Biologics Announces its 2021 Financial Calendar"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-19T00:34:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GenSight Biologics Announces its 2021 Financial Calendar\",\"datePublished\":\"2021-01-19T00:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/\",\"name\":\"GenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-19T00:34:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-its-2021-financial-calendar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics Announces its 2021 Financial Calendar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/","og_locale":"en_US","og_type":"article","og_title":"GenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk","og_description":"GenSight Biologics Announces its 2021 Financial Calendar PARIS–(BUSINESS WIRE)– Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021. Information Date* 2020 4Q Cash Position January 19, 2021 2020 Full-Year Financial Update and Statements March 10, 2021 2021 1Q Cash Position April 20, 2021 Annual General Meeting April 29, 2021 2021 First-Half Financial Update and Statements July 29, 2021 2021 3Q Cash Position October 19, 2021 2021 4Q Cash Position January 18, 2022 * This financial calendar is provided for information only and may be subject to changes. The Company\u2019s updated financial … Continue reading \"GenSight Biologics Announces its 2021 Financial Calendar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-19T00:34:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GenSight Biologics Announces its 2021 Financial Calendar","datePublished":"2021-01-19T00:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/"},"wordCount":324,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/","name":"GenSight Biologics Announces its 2021 Financial Calendar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-19T00:34:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210118005442r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-its-2021-financial-calendar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics Announces its 2021 Financial Calendar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=416171"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/416171\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=416171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=416171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=416171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}